Suzhou Basecare Medical Corporation (2170) Stock Overview

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted human reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides CNV kits, a reagent kit to test abortive tissues for a comprehensive panel of copy number variations for miscarriage. It also offers liquid nitrogen storage dewar, Cryopreservation system, and sperm quality analyzer; and universal kits for sequencing effects, sample preservation solution, nucleic acid purification and DNA extraction kits. The company also engages in the research, development, manufacture, and sale of testing kits, testing devices, and instruments. In addition, it provides marketing services; and engages in the research and development of software for r testing devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.